ALZN — Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 4
- Website: https://www.alzamend.com
Latest SEC filings for ALZN
- RW — 2026-10-09
- 10-Q — 2026-09-10
- S-1 — 2026-08-21
- S-1 — 2026-08-21
- 5 — 2026-08-05
- 5 — 2026-08-05
- 5 — 2026-08-05
- 3 — 2026-08-05
- 8-K — 2026-08-03
- 10-K — 2026-07-22
Latest ALZN news
- — Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks Investment Research)
- — Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? (zacks.com)
Educational tool only — not investment advice.